Atea Pharmaceuticals (AVIR)

• Market cap: $425M
• 1 day: -1.84%
• 5 days: -10.72%
• 1 month: 13.89%
• 3 months: 46.03%
• 6 months: 81.91%
• Year to date: 53.16%
• 1 year: 67.61%
• 5 years: -91.14%
• 10 years: -82.43%
• Sector: Healthcare
• Industry: Biotechnology

About: Atea Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of oral antiviral therapies for serious viral diseases. The company's pipeline includes a regimen of bemnifosbuvir and ruzasvir for the treatment of hepatitis C virus (HCV) infection and AT-587 for the treatment of hepatitis E virus (HEV) infection.

Employees: 55